Palisade Bio Stock Today

PALI Stock  USD 4.15  0.14  3.26%   


0 of 100

Very Weak

Odds Of Distress

Over 85

Very High
Palisade Bio is trading at 4.15 as of the 25th of July 2024. This is a 3.26 percent decrease since the beginning of the trading day. The stock's open price was 4.29. Palisade Bio has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Palisade Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of May 2023 and ending today, the 25th of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
20th of December 2006
Health Care
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. The company has 936.4 K outstanding shares of which 23.78 K shares are at this time shorted by private and institutional investors with about 1.0 trading days to cover. More on Palisade Bio

Moving together with Palisade Stock

  0.8CANB Can B CorpPairCorr

Moving against Palisade Stock

  0.83WMT Walmart Sell-off TrendPairCorr
  0.78AIBBU AIB Acquisition CorpPairCorr
  0.7T ATT Inc Buyout TrendPairCorr
  0.69BAC Bank of America Fiscal Year End 10th of January 2025 PairCorr
  0.64MACAU Moringa Acquisition CorpPairCorr
  0.6ACACU Acri Capital AcquisitionPairCorr

Palisade Stock Highlights

ESG Sustainability
CEO DirectorJ Finley
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.03720.0205
Way Up
Slightly volatile
Total Current Liabilities3.4 M2.6 M
Significantly Up
Very volatile
Non Current Liabilities Total145.3 K153 K
Notably Down
Very volatile
Total Assets12.3 M14.1 M
Fairly Down
Very volatile
Total Current Assets11.2 M13.2 M
Fairly Down
Very volatile
Debt Levels
Palisade Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Palisade Bio's financial leverage. It provides some insight into what part of Palisade Bio's total assets is financed by creditors.
Palisade Bio currently holds 369 K in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. Palisade Bio has a current ratio of 2.54, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Palisade Bio's use of debt, we should always consider it together with its cash and equity.

Change In Working Capital

Palisade Bio (PALI) is traded on NASDAQ Exchange in USA. It is located in 7750 El Camino Real, Carlsbad, CA, United States, 92009 and employs 9 people. Palisade Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.04 M. Palisade Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 936.4 K outstanding shares of which 23.78 K shares are at this time shorted by private and institutional investors with about 1.0 trading days to cover. Palisade Bio currently holds about 5 M in cash with (11.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.23.
Check Palisade Bio Probability Of Bankruptcy
Ownership Allocation
Roughly 87.0 pct. of Palisade Bio outstanding shares are held by general public with 2.88 % owned by insiders and only 10.57 (%) by third-party entities.
Check Palisade Ownership Details

Palisade Stock Institutional Holders

InstituionRecorded OnShares
Morgan Stanley - Brokerage Accounts2024-03-31
Virtu Financial Llc2024-03-31
Advisor Group Holdings, Inc.2023-12-31
Two Sigma Securities, Llc2024-03-31
Northwestern Mutual Wealth Management Co2024-03-31
Vanguard Group Inc2023-12-31
68.1 K
Geode Capital Management, Llc2023-12-31
34.4 K
State Street Corporation2023-12-31
22.5 K
Ubs Group Ag2023-12-31
2.5 K
Wells Fargo & Co2023-12-31
Fmr Inc2023-12-31
View Palisade Bio Diagnostics

Palisade Bio Historical Income Statement

As of now, Palisade Bio's Research Development is increasing as compared to previous years. The Palisade Bio's current Total Operating Expenses is estimated to increase to about 15.4 M, while Interest Expense is projected to decrease to under 14.2 K. View More Fundamentals

Palisade Stock Against Markets

Palisade Bio Corporate Management

Ryker WillieSenior ControllerProfile
Sharon McBrayerDirector OperationsProfile
Mitchell MDChief OfficerProfile
Robert McRaeVP DevelProfile
MD FAAAAIChief OfficerProfile

Additional Information and Resources on Investing in Palisade Stock

When determining whether Palisade Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Palisade Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Palisade Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Palisade Bio Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Palisade Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Palisade Bio. If investors know Palisade will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Palisade Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Return On Assets
Return On Equity
The market value of Palisade Bio is measured differently than its book value, which is the value of Palisade that is recorded on the company's balance sheet. Investors also form their own opinion of Palisade Bio's value that differs from its market value or its book value, called intrinsic value, which is Palisade Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Palisade Bio's market value can be influenced by many factors that don't directly affect Palisade Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Palisade Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Palisade Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Palisade Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.